Pfizer Retained Earnings increased by 2.3% to $117.24B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.0%, from $119.59B to $117.24B. Over 5 years (FY 2020 to FY 2025), Retained Earnings shows an upward trend with a 4.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase signals strong historical profitability and reinvestment, while a decrease may indicate losses or significant dividend payouts.
This represents the cumulative net income earned by the company since its inception, minus any dividends paid to shareho...
A key metric for all established companies; growth rates are compared against peers to gauge long-term success.
retained_earnings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $96.35B | $102.25B | $103.39B | $111.19B | $116.61B | $122.97B | $125.66B | $131.10B | $128.80B | $126.41B | $118.35B | $121.32B | $116.60B | $121.06B | $116.73B | $119.59B | $117.61B | $121.15B | $114.61B | $117.24B |
| QoQ Change | — | +6.1% | +1.1% | +7.5% | +4.9% | +5.5% | +2.2% | +4.3% | -1.8% | -1.9% | -6.4% | +2.5% | -3.9% | +3.8% | -3.6% | +2.5% | -1.7% | +3.0% | -5.4% | +2.3% |
| YoY Change | — | — | — | — | +21.0% | +20.3% | +21.5% | +17.9% | +10.5% | +2.8% | -5.8% | -7.5% | -9.5% | -4.2% | -1.4% | -1.4% | +0.9% | +0.1% | -1.8% | -2.0% |